ET21000361

GS-US-587-6156: Ph II_ Magrolimab + Beva et FOLFIRI vs beva + folfiri_ colorectal méta

Description de l'étude : 

GS-US-587-6156: A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (CRC)

Médecin coordonnateur : Dr Clélia Coutzac

Co-investigateurs : Dr Cassier, Dr Coutzac, Dr Rochefort, Dr Lledo, Dr Streichenberger, Dr Cattey

N° Promoteur : SKYSCRAPER-O7 (YO42137)